Jiangsu Hualan New Pharmaceutical Material Co.,Ltd. (SHE:301093)

SHE:301093 Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020
Operating Revenue	602.9	584.45	621.9	583.67	819.27	443.65
Other Revenue	1.96	1.96	1.03	0.47	1.6	2.67
Revenue	604.86	586.41	622.92	584.14	820.87	446.32
Revenue Growth (YoY)	2.18%	-5.86%	6.64%	-28.84%	83.92%	-2.92%
Cost of Revenue	375.9	363.66	367.57	334.13	373.85	240.55
Gross Profit	228.96	222.76	255.36	250	447.02	205.77
Selling, General & Admin	145.73	145.52	145.13	139.3	141.4	76.23
Research & Development	40.2	39.54	36.18	36.69	42.08	23.66
Other Operating Expenses	5.85	4.06	3.41	6.14	8.82	6.14
Operating Expenses	192.93	189.58	183.67	183.7	194.68	106.5
Operating Income	36.03	33.18	71.68	66.3	252.34	99.27
Interest Expense	-0.81	-0.25	-0.44	-0.6	-4.83	-6.8
Interest & Investment Income	11.03	22.05	48.2	14.89	3.74	0.24
Currency Exchange Gain (Loss)	-2.81	-2.81	1.95	1.4	0.72	-1.37
Other Non Operating Income (Expenses)	4.1	-0.58	-0.42	-0.27	-1.31	-0.95
EBT Excluding Unusual Items	47.54	51.58	120.97	81.72	250.66	90.38
Gain (Loss) on Sale of Investments	10.58	5.85	3.26	25.83	-	-
Gain (Loss) on Sale of Assets	-0.56	0	0.21	0.27	-0.02	1.51
Asset Writedown	1.22	-0.05	-0.04	-0.84	-	-
Other Unusual Items	1.17	1.17	12.87	0.35	2.38	3.87
Pretax Income	59.95	58.55	137.27	107.33	253.02	95.76
Income Tax Expense	9.39	8.98	19.34	13.58	37	14.41
Earnings From Continuing Operations	50.56	49.57	117.93	93.75	216.02	81.36
Minority Interest in Earnings	0.09	0	-	-	-	-
Net Income	50.65	49.57	117.93	93.75	216.02	81.36
Net Income to Common	50.65	49.57	117.93	93.75	216.02	81.36
Net Income Growth	-37.36%	-57.96%	25.79%	-56.60%	165.52%	-14.52%
Shares Outstanding (Basic)	164	167	175	175	139	131
Shares Outstanding (Diluted)	164	167	177	175	139	131
Shares Change (YoY)	-3.81%	-5.83%	0.98%	26.34%	5.62%	-0.10%
EPS (Basic)	0.31	0.30	0.67	0.54	1.56	0.62
EPS (Diluted)	0.31	0.30	0.67	0.54	1.56	0.62
EPS Growth	-34.88%	-55.36%	24.56%	-65.65%	151.39%	-14.44%
Free Cash Flow	-63.37	-14.65	-73.39	-78.73	92.78	93.86
Free Cash Flow Per Share	-0.39	-0.09	-0.41	-0.45	0.67	0.71
Dividend Per Share	0.154	0.154	0.462	0.231	0.538	-
Dividend Growth	-66.67%	-66.67%	99.70%	-57.08%	-	-
Gross Margin	37.85%	37.99%	40.99%	42.80%	54.46%	46.10%
Operating Margin	5.96%	5.66%	11.51%	11.35%	30.74%	22.24%
Profit Margin	8.37%	8.45%	18.93%	16.05%	26.32%	18.23%
Free Cash Flow Margin	-10.48%	-2.50%	-11.78%	-13.48%	11.30%	21.03%
EBITDA	99.58	88.54	116.13	101.15	280.45	128.72
EBITDA Margin	16.46%	15.10%	18.64%	17.32%	34.16%	28.84%
D&A For EBITDA	63.55	55.36	44.45	34.84	28.11	29.45
EBIT	36.03	33.18	71.68	66.3	252.34	99.27
EBIT Margin	5.96%	5.66%	11.51%	11.35%	30.74%	22.24%
Effective Tax Rate	15.66%	15.33%	14.09%	12.65%	14.62%	15.04%
Revenue as Reported	604.86	586.41	622.92	584.14	820.87	446.32
Advertising Expenses	-	0.53	1.07	2.57	1.69	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.